Global Companion Cancer Diagnostics Market Size, Status and Forecast 2020-2026

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Companion Cancer Diagnostics Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Companion Cancer Diagnostics Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Breast Cancer
  • 1.4.3 Lung Cancer
  • 1.4.4 Colorectal Cancer
  • 1.4.5 Melanoma
  • 1.4.6 Gastric Cancer
• 1.5 Market by Application
  • 1.5.1 Global Companion Cancer Diagnostics Market Share by Application: 2020 VS 2026
  • 1.5.2 Pharmaceutical & Biopharmaceutical Companies
  • 1.5.3 Reference Laboratories
  • 1.5.4 CROs
  • 1.5.5 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends by Regions

• 2.1 Companion Cancer Diagnostics Market Perspective (2015-2026)
• 2.2 Companion Cancer Diagnostics Growth Trends by Regions
  • 2.2.1 Companion Cancer Diagnostics Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Companion Cancer Diagnostics Historic Market Share by Regions (2015-2020)
  • 2.2.3 Companion Cancer Diagnostics Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Companion Cancer Diagnostics Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Companion Cancer Diagnostics Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Companion Cancer Diagnostics Players by Market Size
  • 3.1.1 Global Top Companion Cancer Diagnostics Players by Revenue (2015-2020)
  • 3.1.2 Global Companion Cancer Diagnostics Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Companion Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Companion Cancer Diagnostics Market Concentration Ratio
  • 3.2.1 Global Companion Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Companion Cancer Diagnostics Revenue in 2019
• 3.3 Companion Cancer Diagnostics Key Players Head office and Area Served
• 3.4 Key Players Companion Cancer Diagnostics Product Solution and Service
• 3.5 Date of Enter into Companion Cancer Diagnostics Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Companion Cancer Diagnostics Historic Market Size by Type (2015-2020)
• 4.2 Global Companion Cancer Diagnostics Forecasted Market Size by Type (2021-2026)

5 Companion Cancer Diagnostics Breakdown Data by Application (2015-2026)

• 5.1 Global Companion Cancer Diagnostics Market Size by Application (2015-2020)
• 5.2 Global Companion Cancer Diagnostics Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Companion Cancer Diagnostics Market Size (2015-2020)
• 6.2 Companion Cancer Diagnostics Key Players in North America (2019-2020)
• 6.3 North America Companion Cancer Diagnostics Market Size by Type (2015-2020)
• 6.4 North America Companion Cancer Diagnostics Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Companion Cancer Diagnostics Market Size (2015-2020)
• 7.2 Companion Cancer Diagnostics Key Players in Europe (2019-2020)
• 7.3 Europe Companion Cancer Diagnostics Market Size by Type (2015-2020)
• 7.4 Europe Companion Cancer Diagnostics Market Size by Application (2015-2020)

8 China

• 8.1 China Companion Cancer Diagnostics Market Size (2015-2020)
• 8.2 Companion Cancer Diagnostics Key Players in China (2019-2020)
• 8.3 China Companion Cancer Diagnostics Market Size by Type (2015-2020)
• 8.4 China Companion Cancer Diagnostics Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Companion Cancer Diagnostics Market Size (2015-2020)
• 9.2 Companion Cancer Diagnostics Key Players in Japan (2019-2020)
• 9.3 Japan Companion Cancer Diagnostics Market Size by Type (2015-2020)
• 9.4 Japan Companion Cancer Diagnostics Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Companion Cancer Diagnostics Market Size (2015-2020)
• 10.2 Companion Cancer Diagnostics Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Companion Cancer Diagnostics Market Size by Type (2015-2020)
• 10.4 Southeast Asia Companion Cancer Diagnostics Market Size by Application (2015-2020)

11 India

• 11.1 India Companion Cancer Diagnostics Market Size (2015-2020)
• 11.2 Companion Cancer Diagnostics Key Players in India (2019-2020)
• 11.3 India Companion Cancer Diagnostics Market Size by Type (2015-2020)
• 11.4 India Companion Cancer Diagnostics Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Companion Cancer Diagnostics Market Size (2015-2020)
• 12.2 Companion Cancer Diagnostics Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Companion Cancer Diagnostics Market Size by Type (2015-2020)
• 12.4 Central & South America Companion Cancer Diagnostics Market Size by Application (2015-2020)

13Key Players Profiles

• 13.1 F. Hoffmann-La Roche
  • 13.1.1 F. Hoffmann-La Roche Company Details
  • 13.1.2 F. Hoffmann-La Roche Business Overview and Its Total Revenue
  • 13.1.3 F. Hoffmann-La Roche Companion Cancer Diagnostics Introduction
  • 13.1.4 F. Hoffmann-La Roche Revenue in Companion Cancer Diagnostics Business (2015-2020))
  • 13.1.5 F. Hoffmann-La Roche Recent Development
• 13.2 Agilent Technologies
  • 13.2.1 Agilent Technologies Company Details
  • 13.2.2 Agilent Technologies Business Overview and Its Total Revenue
  • 13.2.3 Agilent Technologies Companion Cancer Diagnostics Introduction
  • 13.2.4 Agilent Technologies Revenue in Companion Cancer Diagnostics Business (2015-2020)
  • 13.2.5 Agilent Technologies Recent Development
• 13.3 QIAGEN
  • 13.3.1 QIAGEN Company Details
  • 13.3.2 QIAGEN Business Overview and Its Total Revenue
  • 13.3.3 QIAGEN Companion Cancer Diagnostics Introduction
  • 13.3.4 QIAGEN Revenue in Companion Cancer Diagnostics Business (2015-2020)
  • 13.3.5 QIAGEN Recent Development
• 13.4 Abbott Laboratories
  • 13.4.1 Abbott Laboratories Company Details
  • 13.4.2 Abbott Laboratories Business Overview and Its Total Revenue
  • 13.4.3 Abbott Laboratories Companion Cancer Diagnostics Introduction
  • 13.4.4 Abbott Laboratories Revenue in Companion Cancer Diagnostics Business (2015-2020)
  • 13.4.5 Abbott Laboratories Recent Development
• 13.5 Almac Group
  • 13.5.1 Almac Group Company Details
  • 13.5.2 Almac Group Business Overview and Its Total Revenue
  • 13.5.3 Almac Group Companion Cancer Diagnostics Introduction
  • 13.5.4 Almac Group Revenue in Companion Cancer Diagnostics Business (2015-2020)
  • 13.5.5 Almac Group Recent Development
• 13.6 Danaher Corporation
  • 13.6.1 Danaher Corporation Company Details
  • 13.6.2 Danaher Corporation Business Overview and Its Total Revenue
  • 13.6.3 Danaher Corporation Companion Cancer Diagnostics Introduction
  • 13.6.4 Danaher Corporation Revenue in Companion Cancer Diagnostics Business (2015-2020)
  • 13.6.5 Danaher Corporation Recent Development
• 13.7 bioMérieuxSA
  • 13.7.1 bioMérieuxSA Company Details
  • 13.7.2 bioMérieuxSA Business Overview and Its Total Revenue
  • 13.7.3 bioMérieuxSA Companion Cancer Diagnostics Introduction
  • 13.7.4 bioMérieuxSA Revenue in Companion Cancer Diagnostics Business (2015-2020)
  • 13.7.5 bioMérieuxSA Recent Development
• 13.8 Myriad Genetics
  • 13.8.1 Myriad Genetics Company Details
  • 13.8.2 Myriad Genetics Business Overview and Its Total Revenue
  • 13.8.3 Myriad Genetics Companion Cancer Diagnostics Introduction
  • 13.8.4 Myriad Genetics Revenue in Companion Cancer Diagnostics Business (2015-2020)
  • 13.8.5 Myriad Genetics Recent Development

14Analyst's Viewpoints/Conclusions

15Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer